Physician profile
Arwa Alsamarae
NPI 1487072534
$1,028.75
in general payments reported to CMS, 2019-2025
14 companies · $130 in 2025
The $130 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $39.29 · 2020: $37.79 · 2021: $326 · 2022: $199 · 2023: $154 · 2024: $142 · 2025: $130.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $426.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $426.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $554.13 | 2019-2025 | Rocklatan, Clareon |
| Aerie Pharmaceuticals, INC. | $102.61 | 2020-2021 | |
| Biotissue Holdings INC. | $67.72 | 2022-2024 | |
| Bausch & Lomb Americas INC. | $49.24 | 2022-2025 | Vyzulta, Miebo |
| Abbvie INC. | $37.81 | 2025 | |
| Allergan, INC. | $35.29 | 2021 | |
| Novartis Pharmaceuticals Corporation | $31.17 | 2020-2022 | |
| Oyster Point Pharma, INC. | $30.17 | 2023 | Tyrvaya |
| Thea Pharma INC. | $24.01 | 2023 | Iyuzeh |
| Horizon Therapeutics Plc | $23.91 | 2023 | Tepezza |
| Amgen INC. | $22.07 | 2024 | Tepezza |
| Johnson & Johnson Surgical Vision, INC. | $19.93 | 2024 | Tecnis Iol, Tecnis Simplicity |
| Sun Pharmaceutical Industries INC. | $17.14 | 2023 | Cequa |
| Sight Sciences, INC. | $13.55 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arwa Alsamarae listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.